Updated:
HeartBeam, Inc.
HeartBeam, Inc. is a medical-device company developing a credit-card-sized ECG for heart-attack detection, led by founder Branislav Vajdic.
HeartBeam, Inc.
HeartBeam, Inc. was founded by Branislav Vajdic, an electrical engineer who previously led R&D at a multinational medical-device firm. The company is incorporated in Delaware and maintains its operational headquarters in Santa Clara, California. Cardiac monitoring is the sole focus; no family-office or asset-management function has been disclosed. The firm's core technology is a credit-card-sized ECG device paired with a cloud-based AI interpretation platform. It targets the coronary-artery-disease market, which covers millions of patients presenting with chest pain annually. Clinical trials have been conducted at sites including the Cleveland Clinic and Mayo Clinic (per ClinicalTrials.gov, 2023). HeartBeam does not publish a total addressable market figure nor disclose capital deployed beyond what is in SEC filings. HeartBeam has raised at least $24M through a 2021 SPAC merger that took it public. The company had approximately 15 employees as of its 2023 annual report (per SEC filing, March 2024). Branislav Vajdic serves as CEO and holds a significant equity stake through founder shares. No philanthropic arm or affiliated entity has been publicly identified. HeartBeam is structured as a publicly traded corporation, not a family office. Its governance follows Nasdaq rules with a board of directors elected by shareholders. This transparency through SEC disclosures is a structural differentiator from privately held family offices that reveal little.
General information
Firm type
other
Year founded
—
AUM
Undisclosed
Location
Region
North America
Country
United States
City
Santa Clara
Corporate office
Santa Clara, CA, United States
Principals
Branislav Vajdic
CEO and Founder
Sector focus
Frequently asked questions
Is HeartBeam a family office or an investment firm?
No. HeartBeam is a publicly traded medical-device company (Nasdaq: BEAT). It does not manage third-party capital and has no investment function. It is included in this database because its name appears in some fund investor lists, though no family-office structure has been confirmed.
What does HeartBeam's device do that existing ECGs do not?
HeartBeam's AIMIGo device records a 12-lead ECG in a compact form factor that patients can use at home. The system transmits vector-ECG data to a cloud-based AI for interpretation, targeting earlier detection of STEMI heart attacks outside hospitals.
What regulatory approvals has HeartBeam received?
HeartBeam received FDA 510(k) clearance for the AIMIGo device in October 2024 (per FDA, October 2024). The company has also obtained CE marking for the European market.
Who are HeartBeam's clinical partners?
HeartBeam has cited clinical collaborations with the Cleveland Clinic, Mayo Clinic, and the University of California, San Francisco in its clinical trial registrations and press releases (per ClinicalTrials.gov, 2023).
How is HeartBeam funded?
HeartBeam went public via a SPAC merger in 2021, raising approximately $24M. It has not disclosed additional private capital raises beyond what appears in SEC filings. The company is not venture-backed in the traditional sense, with founder and public-market shareholders as the primary capital sources.
Profile maintained by Altss using OSINT (open-source intelligence), regulatory filings, licensed data partners, and verified direct submissions. Read the methodology. Last updated: . Continuous refresh with full update cycles at least every 30 days.
Need institutional-grade insight on family offices?
Altss delivers:
Prefer a guided tour?
We’ll walk you through: